Avacta Group make significant progress with its highly scalable lateral flow test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins us to discuss its update on the lateral flow rapid antigen test. Alastair reminds us of the COVID-19 tests that it is developing, talks us through the key points of todays update, progress made with the other tests taking the first preCISION pro drug programme into the clinic and what other updates we can expect.

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100 billion. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

The company’s pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta Group expects to take its first drug, a pre|CISION targeted form of the standard-of-care doxorubicin, into the clinic in early 2021.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Innovations in neutralising therapies

Coronaviruses are a large family of viruses that cause illnesses like the common cold, but can also cause more severe diseases such as Middle East Respiratory Syndrome (MERS) and Sever Acute Respiratory Syndrome (SARS). The novel

Avacta Group Plc

Biopharma update on the novel Coronavirus – July

Testing Therapies, Antivirals and Vaccines Avacta Group has partnered with the U.K. government’s CONDOR program to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry laboratory assay developed with Adeptrix. Adeptrix’s novel BAMS platform uses

Avacta Group Plc

Biopharma update on the novel Coronavirus

Testing Therapies, Antivirals and Vaccines Avacta Group entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert

Avacta Group Plc

Commercial potential for waste water Covid-19 detection

Life sciences business Avacta Group has become the second Yorkshire firm to partner with Integumen on Covid-19 detection systems for wastewater. The Wetherby-based listed firm has entered into a collaboration agreement with Integumen to evaluate its

Avacta Group Plc

preCISION and Affimer based cancer therapies

In this interview, Alastair Smith discusses our development of a rapid antigen test for SARS-Cov-2 and the progress of our preCISIONTM and Affimer® based cancer therapies. Watch below.  Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology

Avacta Group Plc

Avacta Group wins Small Cap award

Avacta Group has won Technology Company of the Year at the Small Cap 2020 Awards. Over 200 attendees, all supporters of the small cap community congregated online at the (optional) black tie event. Companies and advisors

Avacta Group Plc

How diagnostic test performance is measured

In this video, Avacta’s Chief Executive Officer Alastair Smith explains how diagnostic test performance is measured. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United

Avacta Group Plc

The Quest for a Cure

In 2003, the outbreak of severe acute respiratory syndrome (SARS) became the first pandemic of the 21st century and exemplified the rapid rate at which a virus can spread internationally. Originating in China, SARS quickly spread